3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases.
-
Citations
57 Claims
-
1-18. -18. (canceled)
-
19. A method of treating a disease or disorder selected from an autoimmune disease, cancer, a myeloproliferative disorder, an inflammatory disease, a viral disease, organ transplant rejection, ischemia reperfusion or a disease related to an ischemic event, anorexia, cachexia fatigue resulting from or associated with cancer, allograft rejection or graft versus host, rheumatoid arthritis, psoriasis, dermatitis, iritis, uveitis, scleritis, and conjuctivitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile;
- and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile;
or a pharmaceutically acceptable salt thereof. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
- and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile;
- 50. A process for preparing a phosphoric acid salt of a compound of Formula III:
Specification